|
|
Calling All CounterPunchers!
|
home / subscribe / donate / books / archives / search / links / feedback / events / faq
Calling All CounterPunchers!
Nearing the Half-Way PointWe are now entering our second week of fundraising. As you can see from the donation gauge there on the right, some of you have given us a great start. Some of you, but not enough of you! To those
who have not yet given, CounterPunch needs your financial support!
Either we meet our fundraising goal of $75,000 over the next two weeks or we'll be forced to drastically curtail the operation of our website.
CounterPunch's website is supported almost entirely by subscribers to the print edition of our newsletter. Yes, the continued existence of CounterPunch depends solely on the support and dedication of our readers. And we know there are a lot of you. We get thousands of emails from you every day. Our website receives millions of hits and nearly 100,000 readers each day-and those numbers grow by the month.
Unlike many other outfits, we don't hit you up for money every month ... or even every quarter, like our friends at Antiwar.com. We only ask for your support once a year. But when we ask, we mean it. Please, use our secure server make a tax-deductible donation to CounterPunch today or purchase a subscription and a gift sub for someone or one of our award-winning books (or a crate of books!) as holiday presents. (We won't call you to shake you down or sell your name to any lists--even Dick Cheney's.)
To contribute by phone you can call Becky or Deva toll free at: 1-800-840-3683
Onward,
Alexander, Jeffrey, Becky, Alya, Deva and Kimberly
CounterPunch
PO Box 228, Petrolia, CA 95558
|
Today's Stories November 3, 2008 Patrick Cockburn October 31 , 2008 Alexander Cockburn Jeffrey St. Clair Douglas Valentine Ismael Hossein-Zadeh Dr. Ignacy Nowopolski Alan Maass William P. O’Connor Patrick Irelan Brian Cloughley Mats Svensson Binoy Kampmark Steve Conn Alan Farago Morton Skorodin Robert Bryce Wajahat Ali David Yearsley Dennis Loo Pam Martens Stephen Martin Richard Rhames Ramzy Baroud Missy Beattie Howard Lisnoff Richard Neville Saul Landau / Kim Nicolini Lorenzo Wolff Poets' Basement Website of the Weekend October 30, 2008 Cockburn / St. Clair Vijay Prashad Paul Craig Roberts Glen Ford Stanley Heller William Loren Katz Joshua Frank James McEnteer Felice Pace Jonathan Cook Reza Fiyouzat Website of the Day
October 29, 2008 Arno J. Mayer Eric Toussaint Matt Gonzalez Steven Conn Jonathan Cook Patrick Bond Ramzi Kysia Douglas Valentine Stephen Martin Margaret Dooley-Sammuli Amee Chew Website of the Day
October 28, 2008 James G. Abourezk Andy Worthington Gary Leupp Paul Craig Roberts Mike Whitney Gregory V. Button Ralph Nader P. Sainath Martha Rosenberg Charles R. Larson Website of the Day October 27, 2008 Michael Hudson Barbara Rose Johnston John Dinges Mike Whitney Mary Lynn Cramer Greenspan's Higher Power Alan Farago David Michael Green Andy Worthington George Wuerthner Niranjan Ramakrishnan Website of the Day October 24 / 26, 2008 Alexander Cockburn Ishmael Reed Mike Whitney Don Santina Scott Boehm Saul Landau Ron Jacobs Binoy Kampmark Linn Washington Jr. Nicole Colson Bernard Chazelle Brian Jones Christopher Brauchli Benjamin Dangl Val Strange Steve Early David Macaray Allison Kilkenny Richard Rhames Jim Bell Kris De Welde Barry Clemson Adam Engel Mark Scaramella Tuli Kupferberg Lorenzo Wolff Poets' Basement Website of the Weekend October 23, 2008 Allan J. Lichtman Todd Chretien John Ross Peter Morici Mats Svensson Marlene Martin Robert Jensen / Margaret Kimberley Deepak Tripathi David Morris Website of the Day October 22, 2008 Brian Cloughley Heather Gray Jeff Birkenstein Ralph Nader DC Larson David Swanson Keeanga-Yamatta Taylor Race and the Election: When the "Real" America Enters the Voting Booth Larry Everest Robert Fantina Martha Rosenberg Stephen Martin Website of the Day October 21, 2008 Vijay Prashad Paul Craig Roberts Corey D. B. Walker Steve Breyman Eric Toussaint Wajahat Ali Robert Weitzel Brendan Cooney Dave Lindorff Marqueece Harris-Dawson / Bob Wing Patrick B. Barr Omar Barghouti Website of the Day October 20, 2008 Michael Hudson Anthony DiMaggio Tariq Ali Uri Avnery Bill Quigley Ben Rosenfeld David Michael Green William S. Lind Chris Genovali Stephen Martin Howard Lisnoff David Yearsley Website of the Day October 17 / 19, 2008 Alexander Cockburn Jeffrey St. Clair Pam Martens Paul Craig Roberts Mike Whtney Michael D. Yates Suzanne Smith Carl Boggs Ralph Nader Fidel Castro Dave Marsh Saul Landau Jo Guldi Kevin Zeese Larry Everest Steve Early David Macaray Ben Terrall Missy Beattie Don Monkerud Helen Redmond Dan Bacher Wajahat Ali Farzana Versey Vladimir Frolov Kim Nicolini Poets Basement Website of the Day
|
November 3, 2008 Pot ShotsAdieu, RimonabantBy FRED GARDNER The European Medicines Agency (EMEA) has ordered Sanofi-Aventis to stop selling Rimonabant, a drug that reduces appetite by blocking cannabinoid receptors in the brain. Some 700,000 people have taken Rimonabant, which was marketed in the UK and elsewhere as Acomplia. Data from ongoing clinical trials showed that Rimonabant users suffer depression, anxiety, insomnia and aggressive impulses at twice the rate of subjects given placebo. In one study there were five suicides among Rimonabant users compared to only one among subjects on placebo. On Oct. 23 the EMEA said "Enough" in 12 languages. Earlier in October Merck had abruptly canceled five clinical trials of a cannabinoid-blocker called Taranabant. The pattern of adverse psychiatric effects had become too obvious to conceal from U.S. and European regulators. Unpublicized to date are adverse effects involving cancer, seizures, and other illnesses that the cannabinoid system plays a role in suppressing. (In August researchers at the MD Anderson Cancer Center reported that mice on rimonabant develop potentially cancerous polyps at a higher rate than controls.) The dangers of drugs that block cannabinoid receptors were foreseen by California doctors who monitor cannabis use by large numbers of patients. Jeffrey Hergenrather, MD, of Sebastopol, California, was first to go public with his misgivings. Hergenrather had attended the 2004 meeting of the International Cannabinoid Research Society meeting at which Sanofi scientists reported that Rimonabant had proven safe and effective in clinical trials involving 13,000 patients. That year the ICRS's achievement award went to three Sanofi researchers and was presented by Raphael Mechoulam, the grand old man of the field. Many ICRSers got grants from Sanofi and/or the National Institute on Drug Abuse to study the potential of Rimonabant and other cannabinoid-antagonist drugs. Only a few expressed misgivings –off the record— about the basic approach. Hergenrather and Dr. John MacPartland were lonely voices questioning the propriety of Sanofi's march to the market. "The consequences of interfering with the cannabinoid receptor system have not been evaluated in normal human physiology," Hergenrather stated in O'Shaughnessy's (a journal I produce for the Society of Cannabis Clinicians). Hergenrather suggested that before Sanofi marketed Rimonabant, "It would be ethical to design longitudinal studies to assess the consequences of interfering with the cannabinoid system.” The article with Hergenrather's warning first appeared in CounterPunch July 24, 2004. It makes sense that doctors treating patients who augment their cannabinoid levels (by smoking or otherwise ingesting cannabis) would be sensitive to the effects of blocking the receptors they activate. Hergenrather's pro-cannabis colleagues shared his misgivings about Rimonabant, and the late Tod Mikuriya, MD, wrote a letter to the U.S. Food and Drug Administration advising against approval. To FDA's credit, a panel of physicians would unanimously turn down Sanofi's application in 2007. (Their decision was influenced by the belatedly revealed dangers of Vioxx.) The receptors blocked by Rimonabant are prevalent in areas of the brain responsible for emotional control. Why did Sanofi and the scientists who jumped on the Rimonabandwagon think they could depress cannabinoid activity in the limbic system without depressing mood? How did they rationalize their hope that a cannabinoid-antagonist drug would not reverse the beneficial effects of natural cannabinoids? Some hypothesized that when the CB1 receptor is blocked, the endocannabinoids are redirected to other targets. They spoke hopefully of "compensatory mechanisms" that would kick in. Phil Denney, MD, saw a silver lining in the Rimonabant marketing drive. He figured it would serve to educate U.S. doctors about the cannabinoid receptor system, which was discovered in the late 1990s, and has not made it into the curriculum at most medical schools. Denney called his SCC colleagues' attention to a two-page Sanofi ad in JAMA, the Journal of the American Medical Assocation, touting "A newly discovered physiological system… The Endocannabinoid System (ECS)." The ad said that the ECS could be targeted by drugs to combat "Metabolic Syndrome," a cluster of risk factors for diabetes defined by Sanofi marketers as a disease unto itself. The JAMA ad was one of about a dozen that Sanofi ran in medical journals to explain Rimonabant's mechanism of action. It said that the endocannabinoid system "consists of signaling molecules and their receptors, including the cannabinoid receptors (CB1 and CB2)." The CB1 receptors are "located centrally in the brain and peripherally in liver, muscle and adipose tissue" and "may assist in regulating physiologic processes, e.g., lipid and glucose metabolism." But the gusher of enlightenment that Denney anticipated sputtered out quickly. Sanofi did not succeed in defining "Metabolic Disorder" as a real disease the way Eli Lilly had with "Clinical Depression." A nation that had been educated about the serotonin reuptake process did not get equivalent instruction about the cannabinoid receptor system. The information contained in a few medical-journal ads never crossed over into the mass media. In most of the stories dealing with the rise and fall of Rimonabant, reporters avoided the term "cannabinoid receptor system" entirely. For example, in Jeanne Whalen's Oct. 24 Wall St. Journal piece about the EMEA withdrawing approval, she described Rimonabant as "a new kind of drug that blocks receptors in the brain that help control food intake." To those who suspect a conscious decision by Prohibitionist publishers to prevent the public from learning about the cannabinoid receptor system, we say: never underestimate the role of bone-ignorant journalists. In March, 2007, when the FDA was evaluating Rimonabant, Whalen wrote a front-page piece with this doubly inaccurate phrase: "Cannabis, the active ingredient in marijuana, acts on the same receptors… I wrote a polite note to the editor explaining that "cannabis" and "marijuana" are synonyms, and that the plant contains more than one active ingredient. Ms. Whalen emailed back: "Thanks for writing -- always good to hear from readers. I actually didn't mean to get that technical in my phrasing -- I was really just saying that the drug marijuana is made from cannabis. But thank you for the points you made. Best regards, Jeanne Whalen." This woman covers the European pharmaceutical industry for the Wall St. Journal! Has any honor accrued to Hergenrather and the SCC doctors who joined in warning that Rimonabant would induce serious adverse side-effects? Of course not –they are "potdocs." Hergenrather spent part of this past week-end drafting a letter to a Butte County judge who won't allow a patient of his to medicate with cannabis while on probation unless the patient gets a second approval from an orthopedist. The patient is a middle-aged construction worker with a well-documented history of back pain for which he has been hospitalized, treated by chiropractors, acupuncturists, osteopaths, and physical therapists, and prescribed Celebrex, Flexeril, Soma, Valium, Vicodin, Percodan, Percocet, Darvocet, Ultram, ibuprofen, naproxen, etc. Not only is the judge playing doctor, she doesn't understand that orthopedists have no expertise treating pain. Dr. Hergenrather put this much more diplomatically in his letter to her —as diplomatically as he put his warning about Rimonabant in the summer of 2004. Fred Gardner edits O'Shaughnessy's, the pro-cannabis doctors' journal. He refers to Rimonabant in a podcast at http://www.youtube.com/watch?v=qfzdsePa7UA
|
Now Available from CounterPunch Books! Waiting for Lightning
|
